Weekly liposomal irinotecan for advanced Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a weekly dose of a chemotherapy drug wrapped in liposomes (tiny fat bubbles) for people with Ewing sarcoma that has come back or not responded to standard treatments. The goal is to see if this new form of the drug can help when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Ewing sarcoma that has come back or is not responding to treatment.
- You have already received standard chemotherapy for Ewing sarcoma, including drugs like doxorubicin, vincristine, cyclophosphamide, ifosfamide, and etoposide.
- Your cancer is measurable on a CT or MRI scan.
- You are in fairly good health, able to care for yourself (ECOG performance status 0 or 1).
- Your major organs (kidneys, liver, bone marrow, heart) are working well enough, based on recent blood tests.
- Any side effects from your last treatment are mostly gone, and it has been at least 3 weeks since your last chemotherapy or 2 weeks since radiation or major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
This study is testing new drugs for young people (ages 10 and up) with Ewing sarcoma or related tumors that have come back or stopped responding to treatment. The goal is to find promising drugs that may help shrink tumors or slow their growth.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.